Zusammenfassung
Für die vorliegende Literaturübersicht wurden sämtliche Publikationen aus 2013, die sich mit Typ-1-Diabetes beschäftigten, durchgesehen und die 18 für die praktisch-klinische Diabetologie wichtigsten Beiträge ausgewählt. Im Folgenden werden der jeweilige Hintergrund der Arbeit, in übersichtlicher Form die Methoden und das Ergebnis sowie eine Würdigung mit einem Fazit für die Praxis dargestellt.
Abstract
This review extracted the 18 most important publications dealing with diabetes mellitus type 1 from the literature published in 2013. The background of each publication is presented together with the methods and results. Implications for daily practice are provided.
Literatur
Bergenstal RM, Klonoff DC, Garg SK et al (2013) Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 369:224–302
Buckingham D, Beck RW, Ruedy KJ et al (2013) Effectivness of early intensive therapy on β-Cell preservation in Type 1 Diabetes. Diabetes Care 36:4030–4035
Choudhary G, Ramasamy S, Green L et al (2013) Real-time continuous glucose monitoring significant reductions of hypoglycemia in hypoglycemia-unerware-patients with type 1 diabetes. Diabetes Care 36:4160–4162
Damiano IR, El-Khatib FH, Zheng H et al (2013) A comparative effectiveness analysis of three continuous glucose monitors. Diabetes Care 36:251–259
Zeeuw D de, Akizawa T, Audhya P et al (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369:2492–2503
Fredheim S, Johannesen J, Johansen A et al (2013) Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia 56:995–1003
Hietala K, Wadén J, Forsblom C et al (2013) HbA1c-Variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes. Diabetologia 56:737–745
Jacobs-Tulleneers-Thevissen D, Chintinne M, Ling Z et al (2013) Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia 56:1605–1614
Jørgensen ME, Almdal TP, Carstensen B (2013) Time trends in mortality rates in type 1 diabetes from 2002 to 2011. Diabetologia 56:2401–2404
Le Caire TJ, Palta M, Klein R et al (2013) Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study (WDRS) and the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR). Diabetes Care 36:631–637
Ly TT, Nicholas JA, Retterath A et al (2013) Effect of sensor-augmented insulinpump therapy and automated insulin suspension with the standard insulin pump therapy and hypoglycemia inpatient with type 1 diabetes. Randomized, controlled trials. JAMA 310:1240–1247
Mader JK, Birngruber T, Korsatko S et al (2013) Enhanced absorption of insulin as part as the result of a dispersed injection strategy tested in a randomized trial in type 1 diabetic patients. Diabetes Care 36:780–785
Moran A, Bundy B, Becker DJ et al (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 381:1905–1916
Phillip M, Battelino T, Atlas E et al (2013) Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 368:824–833
Schaefer MK, Kossover RA, Perz JF (2013) Sharing insulinpens: are you putting patients at risk? Diabetes Care 36:188–190
Sherr JL, Palau Collazo M, Cengiz E et al (2014) Safety of night time 2 hours suspension of basal insulin in pump treatment type 1 diabetes even in the absence of low glucose. Diabetes Care 37:773–779
Wisting L, Frøisland DH, Skrivarhaug T et al (2013) Disturbed eating behavior and omission of insulin in adolescents receiving intensified insulin treatment: a nationwide population-based study. Diabetes Care 36:3382–3387
Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple autoalted autoantibodies and risk of progression to diabetes in children. JAMA 309:2473–2479
Einhaltung ethischer Richtlinien
Interessenkonflikt. M. Dreyer hat von den Firmen Novo, Lilly und MSD Vortragshonorare erhalten. Der Beitrag enthält keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dreyer, M. Update zum Typ-1-Diabetes. Diabetologe 10, 368–375 (2014). https://doi.org/10.1007/s11428-013-1193-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11428-013-1193-1